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Abstract
Objectives: Report on one-year results from the Polish Spondyloarthritis Initiative registry (PolSPI), 
containing the cross-sectional analysis of clinical and imaging data as well as database methodology.
Material and methods: The PolSPI registry includes patients with axial (axSpA) and peripheral (per-
SpA) spondyloarthritis according to ASAS classification criteria, and/or patients with ankylosing 
spondylitis according to modified New York criteria, psoriatic arthritis according to CASPAR criteria, 
arthropathy in inflammatory bowel disease, reactive arthritis, juvenile spondyloarthritis or undif-
ferentiated spondyloarthritis. Epidemiologic data and history of signs, symptoms and treatment of 
spondyloarthritis are collected and assessment of disease activity is performed. Radiographic imag-
es of sacroiliac joint, cervical and lumbar spine, and results of bone densitometry are collected. Every 
6 months blood samples for inflammatory markers, and for long-term storage are taken.
Results: During a one-year period from September 2015 to August 2016, 63 patients were registered 
on an electronic database; 44 (69.8%) of patients were classified as axial spondyloarthritis (axSpA) and 
19 (30.2%) as peripheral spondyloarthritis (perSpA) according to ASAS criteria. Statistically significant 
differences between axSpA and perSpA were discovered in the percentage of HLA-B27 antigen occur-
rence (92.6% and 50%, respectively), BASDAI (2.8% and 4.1%, respectively), DAS 28 (2.66% and 4.03%, 
respectively), percentage of peripheral arthritis (20% and 88.8%, respectively), enthesitis (26.7% and 
70.6%, respectively), dactylitis (6.7% and 88.9%, respectively), as well as extra-articular symptoms: 
acute anterior uveitis (26.7% and 5.6% , respectively) and psoriasis (6.9% and 55.6%, respectively). 
Patients with axSpA had significantly higher mean grade of sacroiliac involvement according to New 
York criteria, higher mSASSS score, and lower T-score in femoral neck in bone densitometry.
Conclusions: At the early stage of the disease patients with axSpA compared to those with perS-
pA, have more advanced structural damage of sacroiliac joints and spine, and lower bone mineral 
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Introduction
The research group of academic centers – the Polish 
Spondyloarthritis Initiative registry (PolSPI), emerged in 
2014 as a group of scientists interested in cooperation 
in the field of spondyloarthritis. The collaboration agree-
ment involved 5 academic centers: Jagiellonian University 
Medical College in Krakow, Wroclaw Medical University, 
Pomeranian Medical University in Szczecin, Poznan Uni-
versity of Medical Sciences and Collegium Medicum in 
Bydgoszcz, Nicolaus Copernicus University in Torun. The 
main purpose of PolSPI group is to provide multi-center, 
comprehensive cooperation in the research on spondy-
loarthritis. The collaboration involves research on epide-
miology and other fields, including response to treatment. 
The main research tool is PolSPI registry, a prospective da-
tabase including clinical, imaging and laboratory data and 
treatment modalities. Registry was approved by the local 
medical ethics committee of the Jagiellonian University. 
In September 2015, after accomplishing formal require-
ments, i.e. protection of personal data and limited access 
to records, an electronic database has been launched. 
This article reports on one-year results of Polish Spondy-
loarthritis Initiative registry (PolSPI).
Material and methods
The inclusion criteria for PolSPI registry are as fol-
lows: age ≤ 45 years, definite diagnosis of axial (axSpA) 
and/or peripheral (perSpA) spondyloarthritis according 
to Assessment of SpondyloArthritis International Soci-
ety (ASAS) classification criteria [1–3], and/or patients 
with ankylosing spondylitis (AS) according to modified 
New York criteria [4], also with psoriatic arthritis ac-
cording to classification criteria for Psoriatic ARthritis 
(CASPAR) [5]. The registry also includes patients with 
confirmed diagnosis of diseases such as: arthropathy in 
inflammatory bowel disease, reactive arthritis, juvenile 
spondyloarthritis or undifferentiated spondyloarthritis. 
The exclusion criteria are: age > 45 years, inability to 
sign informed consent for participation in a study or to 
follow protocol visit schedule. 
Having obtained information about the aim of the 
registry, patients are asked to sign an informed consent 
of participation in the study and processing of person-
al data. Each patient is allotted an individual number in 
density in the femoral neck. In the upcoming years the PolSPI registry will prospectively follow-up 
patients with SpA, recording response to treatment and carrying out research on interaction of 
inflammation and bone remodelling.
Key words: registry, axial spondyloarthritis, peripheral spondyloarthritis.
the electronic database for identification of electronic 
records and micro-tubes with plasma. During the en-
rolment visit epidemiological and clinical data, includ-
ing age, gender, weight, height, history of smoking and 
alcohol use, comorbidities, family history, detailed his-
tory of signs, symptoms and pharmacologic treatment 
of spondyloarthritis are collected. Physical examination 
of joints (painful and swollen joint count, evidence of 
dactylitis and enthesitis), assessment of spinal range of 
motion using BASMI (Bath Ankylosing Spondylitis Me-
trology Index), assessment of chest wall extension and 
occipital-wall distance, as well as assessment of disease 
activity by BASFI (Bath Ankylosing Spondylitis Functional 
Index), BASDAI (Bath Ankylosing Spondylitis Disease Acti - 
vity Index), ASDAS (Ankylosing Spondylitis Disease Ac-
tivity Score), DAS 28 (Disease Activity Score 28) and HAQ 
(Health Assessment Questionnaire) questionnaires are 
performed. X-ray images of sacroiliac joints and cervical 
and lumbar spine for structural damage assessment by 
mSASSS (modified Stoke Ankylosing Spondylitis Spinal 
Score), and results of bone densitometry by dual-energy 
X-ray absorptiometry (DXA) are collected. During enrol-
ment visit and every 6 months thereafter blood samples 
for inflammatory markers (erythrocyte sedimentation 
rate – ESR, C-reactive protein – CRP), and for long-term 
storage are taken. Subsequent visits are scheduled ev-
ery 6-months – at each visit clinical and laboratory data, 
and update of current treatment are recorded. Accord-
ing to registry protocol, imaging studies will be collect-
ed every 2 years. In 2017 cardiovascular module will be 
added to the registry. The data analysis was performed 
with SAS 9.2 version (SAS Institute Inc. Cary, NC, USA). 
The continuous data are presented as means (SD) and 
compared with Student’s t-test or as percentages and 
compared with c2 test. A p value of < 0.05 was consid-
ered statistically significant.
Results
Over one-year period from September 2015 to Au-
gust 2016, 63 patients were registered on electronic 
web database; 44 (69.8%) of patients were classified as 
having axial spondyloarthritis (axSpA) and 19 (30.2%) as 
peripheral spondyloarthritis (perSpA) according to ASAS 
criteria (Table I). 
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Both groups – with axial and peripheral SpA  – were 
not different with regard to age (years [SD]), 42 (11.4) and 
38.5 (7.7), male gender (%), 75.6 and 60% and disease 
duration (years [SD]), 7.9 (7.4) and 5.6 (6) respectively. 
No significant differences were found in ESR (mm/h 
[SD]), 25.6 (17.7) and 30.4 (18.9) and CRP serum concen-
tration (mg/l [SD]), 10.7 (15.3) and 7.8 (6.2), respectively. 
Statistically significant differences between axSpA and 
perSpA were discovered in the percentage of HLA-B27 
antigen occurrence (92.6% and 50%, p = 0.002), and dis-
eases activity assessment scores: BASDAI (2.8 and 4.1, 
p = 0.04) and DAS 28 (2.66 and 4.03, p = 0.0007), but not 
ASDAS-CRP (SD), 2.4 (1.2) and 2.7 (0.9) (p = 0.25). Statisti-
cally significant differences between axSpA and per SpA 
were discovered in percentage of peripheral arthritis 
(20% and 88.8%), enthesitis (26.7% and 70.6%), dactylitis 
(6.7% and 88.9%), as well as extra-articular symptoms: 
acute anterior uveitis (26.7% and 5.6%) and psoriasis 
(6.9% and 55.6%). So far, in the observed cohort there is 
only one case of SpA associated with Crohn’s disease, 
but the patient also fulfilled the modified New York 
criteria of ankylosing spondylitis and was allocated to 
group of axial SpA. Patients with axSpA had significantly 
higher mean grade of sacroiliac involvement according 
to New York criteria (SD), 2.2 (1.2) vs. 0.6 (0.8) on the 
right side and 2.4 (1.1) vs. 0.5 (0.7) on the left side, as 
well as higher mSASSS score (SD) 8.0 (16.2) vs. 0.7 (0.9). 
These patients had also significantly lower T-score (SD) 
Table I. Baseline characteristics of patients in PolSPI registry
axSpA perSpA p value
n, (%) 44 (69.8) 19 (30.2) NS
Age, mean ±SD years 42 (11.4) 38,5 (7.7) NS
Gender, % male 75.6 60 NS
HLA B27 positive, % 92.6 50 0.002
Duration of symptoms, mean 
(±SD) months
7.9 (7.4) 5.6 (6) NS
Symptoms, %
arthritis 20 88.8 < 0.0001
enthesitis 26.7 70.6 0.003
dactylitis 6.7 88.9 < 0.0001
uveitis 26.7 5.6 0.007
IBD 2,27 0 NA
psoriasis 6.9 55.6 0.002
CRP, mean (±SD) mg/l 10.7 (15.3) 7.8 (6.2) NS
ESR mm/h (±SD) 25.6 (17.7) 30.4 (18.9) NS
BASDAI (0–10 scale), mean 2.8 4.1 p = 0.04
ASDAS-CRP, mean (±SD) 2.4 (1.2) 2.7 (0.9) NS
DAS 28, mean 2.66 4.03 0.0007
SIJ Rx, scale 0–4, SD
Right 2,2 (1.2) 0.6 (0.8) 0.0005
Left 2.4 (1.1) 0.5 (0.7) < 0.0001
mSASSS score (SD) 8.0 (16.2) 0.7 (0.9) 0.007
T-score (SD) femoral neck -0,78 (1,31) 0.58 (1.16) 0.02
T-score (SD) L2–L4 –1.05 (1.37) –0.07 (0.72) NS
axSpA – axial spondyloarthritis; perSpA – peripheral spondyloarthritis; IBD – inflammatory bowel disease; SIJ Rx – grade of sacroiliac 
involvement according to New York criteria
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in femoral neck in bone densitometry, –0.78 (1.31) and 
0.58 (1.16), respectively. We found no differences in bone 
mineral density in lumbar spine between these two 
groups. Among patients with axial SpA, 82.2% fulfilled 
modified New York classification criteria for ankylosing 
spondylitis [4], while in the peripheral SpA 30% of pa-
tients fulfilled CASPAR classification criteria for psoriatic 
arthritis [5].
Discussion
During one year of activity of the registry 63 patients 
were enrolled in 5 academic centers. Agreement of the 
consortium enables the linking of other academic and 
non-academic centers, which gives a good perspec-
tive of including more patients in following years. The 
responsibility of recruitment of other centers lies with 
the Steering Committee with acceptance of Scientific 
Board of PolSPI. To limit observation to “early” forms of 
SpA we implemented the entrance criterion of age ≤ 45 
years. This decision was made for three reasons. First, 
inclusion of patients older than 45 years with disease 
duration frequently over 20 years leads to overestima-
tion of a number of variables in statistical analysis en 
block, mainly outcomes of structural damage in sacroil-
iac joints and spine (mSASSS). It can result in an inade-
quate picture of the whole population, especially taking 
into account a small number of patients. Having at one’s 
disposal a small amount of cases, it is difficult to obtain 
a reliable statistical analysis after dividing patients to 
groups of short or long disease duration. 
Moreover, the exact time-point that divides patients 
into short or long disease duration subgroups is not ob-
vious. In the literature there are no data about the time 
point that divides early and late SpA, and for this reason 
the distinction between early and late SpA was defi-
nitely given up a couple years ago. It has instead been 
agreed to divide patients into low and high disease ac-
tivity subgroups of SpA, which influences the extent and 
rate of structural damage. The second reason, is that the 
most interesting trend area of current research focus on 
early stages of SpA, because it is speculated that in this 
stage pathophysiologic changes impact the phenotype 
of disease (axial or peripheral), as well as response to 
treatment including inhibition of structural damage pro-
gression. 
The third reason to exclude patients over 45 years 
is that it is difficult to follow exact time frames of vari-
ous pharmacological treatment from the past, including 
NSAIDs and DMARDs. The most reliable data concerning 
pharmacological treatment covers the last 10 years, also 
due to better access to source data from primary care 
and other specialists. Consequently, in the interest of 
data reliability and a greater likelihood of providing in-
teresting scientific research, the upper limit of 45 years 
at the time of enrolment to the registry was implement-
ed. In principle, our registry stores detailed clinical and 
imaging data (X-rays of sacroiliac joints and spine, and 
bone densitometry), as well as findings of laboratory 
tests. Mirroring existing registries in other countries, the 
possibility of blood samples banking was approved by 
the Bioethics Committee, and then commenced. This 
will allow future assessment of different biomarkers 
and molecules potentially involved in a network of cyto-
kines and proteins of bone remodelling, presumably es-
sential in the pathophysiology and pathogenesis of SpA. 
In the recent years, a number of registries of rheumat-
ic diseases, including spondyloarthritis have been initiat-
ed all over the world and our registry is largely based on 
available data of these registries. One of the most im-
portant benefits of such databases is the possibility of 
providing long-term, prospective clinical observation in 
a “real-life” population, encompassing large and hetero-
geneous group of patients. Registries, along with clinical 
trials, are currently main source of data concerning effec-
tiveness and adverse effects of biological treatment, and 
other data including epidemiological. The registry may 
also be a tool for both cross-sectional and prospective 
scientific research, in which patients from the database 
serve as a study population or control group. The most 
important European registries of SpA include: the Ger-
man database GESPIC (German Spondyloarthritis Incep-
tion Cohort) [6] – containing mainly patients with axial 
disease, the French database DESIR (Devenir des spon-
dyloarthropaties recentes) [7] – enrolling patients under 
50 years of age with inflammatory back pain, and the 
Spanish database REGISPONSER (Registro espanol de 
espondiloartritis de la sociedad espanola de reumatolo-
gia) [8]. The PolSPI is the first registry of spondyloarthritis 
in Poland, aimed primarily at conducting a prospective, 
comprehensive epidemiological observation, reporting 
modalities and response to treatment, and providing 
cutting-edge research in early stages of spondyloarthri-
tis, focusing particularly the interaction between inflam-
mation and bone remodelling. The PolSPI database focus 
on patients with axial (axSpA) and/or peripheral (perSpA) 
spondyloarthritis according to Assessment of Spondy-
loArthritis International Society (ASAS) classification cri-
teria [1–3], and/or patients with ankylosing spondylitis, 
psoriatic arthritis, arthropathy in inflammatory bowel 
disease, reactive arthritis, juvenile spondyloarthritis or 
undifferentiated spondyloarthritis. 
This article reported on the very first data after one 
year of activity, encompassing epidemiological data and 
clinical profile of respective forms of SpA. In the whole 
group of patients in our registry, 69.8% of patients were 
allocated to axial SpA (in this group 82.2% fulfilled modi-
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fied New York criteria of AS [4], and 17.8% had non-radio-
graphic axial SpA according to ASAS criteria [1, 2]), while 
30.2% of patients were allocated to peripheral SpA (30% 
in this group fulfilled CASPAR criteria of psoriatic arthri-
tis). These proportions are consistent with our expecta-
tions, because the majority of patients with spondyloar-
thritis had axial symptoms resulting from inflammation 
in sacroiliac joints and spine. Relatively small number of 
patients had dominant peripheral symptoms (arthritis, 
enthesitis and/or dactylitis), which conforms in line with 
data from other registries and scientific databases. As 
mentioned, most patients with axial SpA had advanced 
structural damage in the sacroiliac joint allowing to di-
agnose ankylosing spondylitis according to modified 
New York criteria. In the current analysis the mean dura-
tion of symptoms typical for SpA was 7.9 years for axial 
disease and 5.6 years for peripheral disease. Therefore, 
we can assume that our database has included so far 
relatively early cases of SpA, allowing research according 
to our assumption. Actually, a number of patients from 
PolSPI registry have been participating in a project fi-
nanced by the National Science Centre of Poland, ex-
ploring the role of peripheral blood mononuclear cells 
in bone remodelling in patients with axial and periph-
eral spondyloarthritis. Among the differences between 
axial and peripheral SpA, the higher BASDAI score in 
patients with peripheral SpA is surprising. The BAS-
DAI score was evolved and validated to assess the ac-
tivity of ankylosing spondylitis, although as well as 
questions concerning the severity of axial symptoms, 
it includes questions about the symptoms resulting 
from involvement of peripheral joints (question 3) 
and soft tissues as enthesopathy (question 4). Da Costa 
et al. [9] reported higher BASDAI score in patients with 
concomitantly active axial and peripheral symptoms 
(overlapping form of SpA), comparing to purely axial or 
peripheral disease. Taking into account higher DAS28 
score in perSpA, we suppose that the reason for the 
higher BASDAI score in this group results just from more 
evident peripheral involvement, with pain and swelling 
of joints, and enthesopathy. This could also explain the 
lack of difference in ASDAS score, which is supposed to 
be more objective than BASDAI, even though we would 
have expected higher ASDAS score in axial group, be-
cause it was also dedicated to ankylosing spondylitis 
patients. In all, above results necessitate gathering of 
more data for analysis. By contrast, according to our ex-
pectations in patients with axSpA we discovered more 
advanced structural damage in sacroiliac joints, higher 
mSASSS score, and lower T-scores in femoral neck.
These results confirm a suitable clinical allocation 
of patients based on ASAS classification criteria in our 
registry, and suggest different course of these two forms 
of SpA disease. The aim of PolSPI registry in subsequent 
years is to increase our knowledge of the different patho-
physiology and natural course of axial and peripheral 
SpA on their early stages, with particular consideration 
of bone remodelling pathways [10–12]. Moreover, the Pol-
SPI registry will allow an explanation of the relationship 
between disease activity and structural damage. On the 
grounds of current cross-sectional data, it is difficult to 
arbitrarily deduce if a given 45-year-old patient with ad-
vanced structural damage, had rather late-onset but “fast 
progressing” disease, with risk factors of early damage 
i.e. elevated serum CRP or baseline syndesmophytes, or 
rather had an early-onset, but “slow progressing” disease 
with over 20-year duration. As mentioned above, in order 
to provide a precise explanation of this problem, we limit-
ed study population to patients ≤ 45 years old at the mo-
ment of enrolment. The data from one-year observation 
must be considered with regard to its limitation. First, this 
is not a consecutive patient-based but rather random pa-
tient-based research, and as such the data might not be 
considered as epidemiologic. Second, at present the num-
ber of patients is certainly not sufficient for in-depth anal-
ysis but we assume, that having at our disposal a signifi-
cantly larger cohort of patients, we will be able to answer 
several questions in SpA research, including that about 
interaction between inflammation and bone remodelling 
as well as response to different treatment modalities. 
Conclusions
As expected, patients with axial spondyloarthritis at 
early stage of the disease had more advanced structural 
damage of sacroiliac joints and spinen in comparison to 
those with perSpA. Patients with axSpA were more likely 
to have an HLA-B27 (92.6% vs. 50% perSpA) and more of-
ten had uveitis. Similarly, a lower bone mineral density in 
the femoral neck was noted in axSpA group.
Inflammatory bowel disease was observed only in 
the axSpA group, and, as expected enthesopathy, dac-
tylitis and skin psoriasis dominated in the peripher-
al spondyloarthritis group. Interestingly, a higher rate 
of BASDAI was demonstrated in the perSpA but there 
was no statistically significant differences between the 
groups in the activity of inflammatory indicators such 
CRP and ESR. For upcoming years the PolSPI registry will 
prospectively follow-up patients with SpA, recording re-
sponse to treatment and carrying out research on inter-
action of inflammation and bone remodelling.
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